Fig. 6. Effect of ADA injection on day 8 post-immunization on DC activation in vivo.
Two groups of B6 mice (n=6) were immunized with IRBP1–20/CFA and one group was injected i.p. with a single dose of ADA (5U/mouse) and the other with PBS on day 8 post-immunization, then, on day 13 post-immunization, splenic DCs (CD11c+) were prepared using MACS columns.
(A) DCs from ADA-treated and untreated mice were incubated with responder T cells (1 × 106/well) from immunized B6 and TCR-δ−/− mice, then the 48 h culture supernatants were tested for IL-17 (left panel) and IFN-γ (right panel).
(B) DCs from ADA-treated and untreated mice were incubated with γδ T cells from immunized B6 mice and the 48 h culture supernatants tested for IL-17.
(C) DCs from untreated mice (upper panel) or ADA-treated mice (lower panel) were double stained with anti-mouse CD25 and anti-mouse CD11c antibodies and subjected to FACs analysis. Data are from a single experiment, representative of three independent experiments. In A and B, *p < 0.05